Investors



2017 Annual General Meeting

View Investor Presentation


Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

Read More


 |NASDAQ GS SBBP (Common Stock)
$4.70 + 0.20
Stock chart for: SBBP.O.  Currently trading at $4.70 with a 52 week high of $6.24 and a 52 week low of $2.00.
Data provided by Nasdaq. Minimum 15 minutes delayed.



Press Releases



Strongbridge Biopharma plc to Present at the Jefferies 2017 Global Healthcare Conference

May 25, 2017

DUBLIN, Ireland and TREVOSE, Pa., May 25, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceut....

Read More

Strongbridge Biopharma plc Provides Corporate Update and Reports First Quarter 2017 Financial Results

May 16, 2017

~ Strongbridge Commercial Introduction of KEVEYIS® (dichlorphenamide) in Mid-April Shows Encouraging Initial Demand ~ ~ RECORLEV™ (levoketoconazole)....

Read More

View More







© 2016 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA is a trademark of Strongbridge Biopharma plc.
KEVEYIS ® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V7 12/2016

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
info@strongbridgebio.com